This book is a concise guide to gastrointestinal cancers, focussing specifically on endoscopic imaging and treatment. Each chapter discusses the different approaches for endoscopic diagnosis, looking at the etiology, epidemiology, endoscopic techniques and role of endoscopic interventions for all major types of gastrointestinal cancer. Written by a renowned author and editor team from the UK, Europe, USA and Asia this manual includes nearly 200 colour images and illustrations. Also included are two video DVDs of thirteen different endoscopic procedures. Key Features Concise guide to endoscopic imaging, diagnosis and treatment of major gastrointestinal cancers Renowned author and editor team from the UK, Europe, USA and Asia Nearly 200 colour images and illustrations Includes video DVDs of various endoscopic procedures

Handbook of Gastrointestinal Cancers is a practical guide to the management of colorectal, pancreatic, hepatocellular, gastric, and esophageal cancers as well as other cancers of the upper and lower gastrointestinal tract. Edited by a multidisciplinary group of oncologists from leading institutions, this book is an essential day-to-day reference for evidence-based treatment and patient care. The handbook focuses on treatment strategies and approaches to cancerous gastrointestinal tumors that are transforming the recent oncological landscape, including expert-given guidance on methods such as neoadjuvant and adjuvant chemotherapy, surgical transplant, radiation therapy, molecular diagnostic testing leading to molecularly targeted therapy, and immunotherapy. With so many advances in the current field, it is increasingly difficult for early-career practitioners to grasp the entirety of practices and for seasoned oncologists to keep up with newly approved therapies, side effects to treatments, and special clinical management considerations, but this handbook addresses it all. Organized by major gastrointestinal disease sites and featuring “How I Treat” case vignettes from world experts for common and uncommon management considerations, the handbook brings an experience-based perspective to these tough-to-treat areas. The treatment strategies and applications set forth in the chapters are pertinent to situations and decision-making encountered in practice. Handbook of Gastrointestinal Cancers is a valuable resource for medical oncologists, radiation oncologists, and surgeons treating and managing gastrointestinal cancers as well as trainees in medical, radiation, and surgical oncology programs needing an accessible point of care resource. KEY FEATURES: Provides treatment plans and recommendations for each stage of a range of gastrointestinal cancers, including colorectal, pancreatic, and hepatocellular cancers plus more Includes “How I Treat” patient vignettes told from the physician’s point of view within each clinical chapter Outlines special considerations for the elderly and for survivors of gastrointestinal cancers Highlights important clinical guidance on nutritional and palliative concerns commonly seen in patients with gastrointestinal cancers

Gastrointestinal (GI) malignancies account for a large portion of cancers worldwide. Although incidence of esophageal, gastric, and colorectal cancers has decreased in recent years, pancreatic and liver cancer have increased. The mainstay of GI cancer therapy is chemoradiation and surgery. Despite significant medical advancements, diagnosis and therapy for GI cancers remain challenging due to tumor cell resistance to chemoradiotherapy. The tumor’s increased cell signalling due to excessive transcription factor activation and increased stellate cell activity leads to collagen deposition formation of a dense stroma around the tumor, which prevents drugs from reaching the malignant cells. This leads to tumor chemoresistance. To circumvent these difficulties, drug therapy targeting the tumor’s specific microenvironment and the additive anticancer effect of phytochemicals can allow for more effective treatment. This volume will be the first on the market on the topic of phytochemicals and their effect on the tumor microenvironment (TME). TME is an emerging area of research and the book will be a welcome introductory addition to the field.

Fully updated to include recent advances in the field, Sleisenger and Fordtran's Gastrointestinal and Liver Disease Review and Assessment, 11th Edition, prepares you for certification and recertification exams using an effective question-and-answer format that follows the ABIM blueprint. Every question reflects current standards of practice and simulates what you’re likely to see on the exam. Use this review tool as a stand-alone resource, or combine it with the Sleisenger and Fordtran's Gastrointestinal and Liver Disease text for further information and study. Contains more than 1,000 board-style (vignette) questions that mimic the ABIM blueprint for the gastroenterology boards, including detailed rationales for each question. Questions are designed to test your medical knowledge, clinical reasoning, interpretation, and problem solving skills. Includes updated coverage of hepatitis B and C, Barrett’s esophagus, colorectal cancer, and enteric microbiota and probiotics. Provides visual support with full-color images throughout, as well as helpful videos online. Features access to an online test component that offers both untimed study mode and timed assessment mode, with detailed answers for a complete interactive experience.

This book covers state-of-the-art topics covering evidences indicate that the gut microbiota can be harnessed for cancer prevention as well as to modulate the efficacy of chemotherapy and immunotherapy. This book includes: 1) characterization of the dysregulated microbiome in gastrointestinal cancers (Chapters 1-6); 2) the molecular mechanism of action of gut microbiota via microbial metabolites and direct interaction with host cancer or immune cells (Chapters 7-11); 3) key methodologies for studying the role of gut microbiota in cancers (Chapters 12-13); and 4) the potential application of gut microbes for the prevention and treatment of gastrointestinal cancers (Chapters 14-17). The contributors are international experts in molecular and cellular biology, microbiology, metabolomics, bioinformatics and physician scientists to provide in-depth reviews of this subject. This book provides a rich resource of information on this important topic for graduate students, basic researchers and physicians.

Recently, immune checkpoint inhibitors (ICIs) have received a lot of attention to treat gastrointestinal cancers. Compared with traditional treatments, immunotherapy can kill cancer cells by activating the antitumor immunity, the specific recognition of cancer antigens preventing normal cells from being attacked. However, the application of ICIs is accompanied by a series of specific toxic reactions caused by the functional stimulation of the immune system, which are called immune-related adverse events (irAEs). Early identification and timely intervention to handle irAEs are usually required to maximize the therapeutic effect of ICIs. In addition, related surgical complications after neoadjuvant immunotherapy is increasingly reported. Thus, although immunotherapy has shown obvious advantages in the clinical treatment of gastrointestinal cancers, the safety and potential risks of such treatment have to be considered. Many clinical studies have shown that cancer patients receiving neoadjuvant immunotherapy experience different degrees of immune-inflammatory reaction, immune disorders, immune-related pneumonia, and other adverse events. In addition, some patients suffering from irAEs during the treatment have to face a delayed operation or even lose the opportunity to be operated. Finally, because the clinical imaging manifestations of immunotherapy are complex and diverse, the imaging evaluation criteria have so far not been standardized. The aim of this Research Topic is to report disputes and challenges of immune checkpoint inhibitors in gastrointestinal cancers. We welcome original research articles, Review articles, Mini Reviews, and Case reports. Preferred topics include but are not limited to the following: • Timely discovery of immune-related adverse events during immunotherapy • Identification and differentiation between immune-related adverse events and adverse drug events • Treatment and drug withdrawal timing upon immune-related adverse events • Management of related surgical complications after neoadjuvant immunotherapy • Imaging evaluation criteria or methods of immunotherapy efficacy